Health and Healthcare

Pfizer : PFE

All Pfizer Articles

1465 Articles

Lee Jackson | Feb 5, 2015 at 10:00 AM EST

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the…

Douglas A. McIntyre | Jan 29, 2015 at 6:55 AM EST

Facebook Still a Small Company

Amidst the excitement about Facebook's nearly 50% revenue growth rate and its successful, accelerating movement into mobile, something is lost.

Chris Lange | Jan 27, 2015 at 8:20 AM EST

Pfizer Faces Reality Check With Earnings

Pfizer reported better-than-expected fourth-quarter earnings Tuesday before the U.S. markets opened.

Paul Ausick | Jan 18, 2015 at 8:20 AM EST

Merck Is Top DJIA Stock in 2015

Merck shares posted a new 52-week high last Tuesday and closed Friday less than a buck from that high. Year…

Paul Ausick | Jan 13, 2015 at 4:01 PM EST

The 4 Stocks That Weighed on the Market Tuesday

thinkstockJanuary 13, 2015: Markets opened higher again on Tuesday but stocks drifted lower all day and finally broke through into…

Jon C. Ogg | Jan 9, 2015 at 11:25 AM EST

The Bullish and Bearish Case for Pfizer in 2015

One key consideration for the year ahead is that the Pfizer of 2016 or 2017 is likely to be night…

Jon C. Ogg | Jan 8, 2015 at 8:15 AM EST

The Bullish and Bearish Case for Johnson & Johnson in 2015

One key consideration for the year ahead is that Johnson & Johnson raised its dividends again and managed to have…

Paul Ausick | Dec 26, 2014 at 4:01 PM EST

The 4 Stocks That Pushed Friday’s Market to New Highs

thinkstockDecember 26, 2014: Markets opened higher on Friday on a morning when it was difficult to find any market-moving news…

Jon C. Ogg | Dec 23, 2014 at 11:25 AM EST

Great Dividends: Meet the Preliminary 2015 Dogs of the Dow

With investors loving dividends so much, 24/7 always tries to take a look at what the Dogs of the Dow…

Jon C. Ogg | Dec 10, 2014 at 10:35 AM EST

What a Generic Celebrex Means for Pfizer and for Actavis

While this was generally a known event coming down the pipe, arthritis drug Celebrex now has a generic competitor in…

Paul Ausick | Dec 5, 2014 at 4:01 PM EST

The 4 Stocks That Carried the Market on Friday

thinkstockDecember 4, 2014: Markets opened higher on Friday after the federal government released a better-than-expected report on employment. Job gains…

Lee Jackson | Dec 3, 2014 at 8:25 AM EST

2014’s Underperforming Large-Cap Stocks That Could Be 2015 Winners

The U.S. equity market is still a great place to be, and the analysts at Jefferies may have a good…

Lee Jackson | Dec 1, 2014 at 8:25 AM EST

Analyst’s 4 Stocks to Buy With Imminent Catalysts

A new report from Jefferies focuses on four stocks to buy that have impending events that could make a difference…

Paul Ausick | Nov 25, 2014 at 4:01 PM EST

The 4 Stocks That Lifted the DJIA

thinkstockNovember 25, 2014: Markets opened higher on Tuesday but the gains were small heading into the long weekend. The second…

Paul Ausick | Nov 18, 2014 at 9:10 AM EST

Companies Spending the Most on R&D

For the third consecutive year, the company spending the most on research and development (R&D) was Germany's Volkswagen.

1 … 60 61 62 63 64 … 98

Pfizer : PFE

All Pfizer Articles

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

Facebook Still a Small Company

Pfizer Faces Reality Check With Earnings

Merck Is Top DJIA Stock in 2015

The 4 Stocks That Weighed on the Market Tuesday

The Bullish and Bearish Case for Pfizer in 2015

The Bullish and Bearish Case for Johnson & Johnson in 2015

The 4 Stocks That Pushed Friday’s Market to New Highs

Great Dividends: Meet the Preliminary 2015 Dogs of the Dow

What a Generic Celebrex Means for Pfizer and for Actavis

The 4 Stocks That Carried the Market on Friday

2014’s Underperforming Large-Cap Stocks That Could Be 2015 Winners

Analyst’s 4 Stocks to Buy With Imminent Catalysts

The 4 Stocks That Lifted the DJIA

Companies Spending the Most on R&D

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

Rivian Tops Q1 Estimates, but Investors Investors Rightly Remain Wary

Ray Dalio Warns U.S. Faces ‘Particularly Risky Period’ Between 2026 and 2028 Elections

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

A Couple With $3.5 Million Discovers State Estate Taxes Could Cost Their Kids Six Figures

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

Rivian Tops Q1 Estimates, but Investors Investors Rightly Remain Wary

Pfizer : PFE

All Pfizer Articles

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

Facebook Still a Small Company

Pfizer Faces Reality Check With Earnings

Merck Is Top DJIA Stock in 2015

The 4 Stocks That Weighed on the Market Tuesday

The Bullish and Bearish Case for Pfizer in 2015

The Bullish and Bearish Case for Johnson & Johnson in 2015

The 4 Stocks That Pushed Friday’s Market to New Highs

Great Dividends: Meet the Preliminary 2015 Dogs of the Dow

What a Generic Celebrex Means for Pfizer and for Actavis

The 4 Stocks That Carried the Market on Friday

2014’s Underperforming Large-Cap Stocks That Could Be 2015 Winners

Analyst’s 4 Stocks to Buy With Imminent Catalysts

The 4 Stocks That Lifted the DJIA

Companies Spending the Most on R&D

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

Rivian Tops Q1 Estimates, but Investors Investors Rightly Remain Wary

Ray Dalio Warns U.S. Faces ‘Particularly Risky Period’ Between 2026 and 2028 Elections

Featured Reads

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

A Couple With $3.5 Million Discovers State Estate Taxes Could Cost Their Kids Six Figures